Woodcock steps in at CDER as Galson departs

Share this article:
To help it implement new FDA reform legislation signed into law in September, the Bush administration has shaken up the leadership of the agency's drug center, whose flounderings over product safety more than anything else provoked passage of the FDA Amendments Act.

Drug center director Steven Galson was elevated to acting surgeon general.

His predecessor, FDA deputy commissioner and chief medical officer Janet Woodcock, who held the post for over a decade until 2005, has returned to the position on a temporary basis.

Galson's tenure was characterized by major public turbulence on the subordination of drug safety reviews to new drug-approval reviews, which he tried to reverse, the Vioxx and David Graham whistleblower controversy, and the uproar over the Plan B emergency contraceptive OTC switch.
FDA commissioner Andrew von Eschenbach told his employees in an e-mail that a national search for a permanent director for the drug center will begin “immediately.”

Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"